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Background: Depression is one of the most frequently missed diagnoses in elderly people, with obvious negative
effects on quality of life. Various studies have shown that long chain omega-3 polyunsaturated fatty acids (n-3 PUFA)
may be useful in its management. Our objective was to evaluate whether a supplement containing n-3 PUFA improves
depressive symptoms in depressed elderly patients, and whether the blood fatty acid pattern is correlated with these
changes.
Methods: The severity of depressive symptoms according to the Geriatric Depression Scale (GDS), blood fatty acid
composition and erythrocyte phospholipids were analyzed in 46 depressed females aged 66-95y, diagnosed with
depression according to DSMIV, within the context of a randomized, double-blind, placebo-controlled trial. 22 depressed
females were included in the intervention group (2.5 g/day of n-3 PUFA for 8 weeks), and 24 in the placebo group. We
also measured immunological parameters (CD2, CD3, CD4, CD8, CD16, CD19 and cytokines (IL-5, IL-15).
Results: The mean GDS score and AA/EPA ratio, in whole blood and RBC membrane phospholipids, were significantly
lower after 2 months supplementation with n-3 PUFA. A significant correlation between the amelioration of GDS and
the AA/EPA ratio with some immunological parameters, such as CD2, CD19, CD4, CD16 and the ratio CD4/CD8, was also
found. Nevertheless, omega-3 supplementation did not significantly improve the studied immunological functions.
Conclusions: n-3 PUFA supplementation ameliorates symptoms in elderly depression. The n-3 PUFA status may be
monitored by means of the determination of whole blood AA/EPA ratio.
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An unbalance in polyunsaturated fatty acid (PUFA) sta-
tus is observed in various pathological conditions, espe-
cially in chronic and/or degenerative diseases associated
with antioxidant system deficiency [1]. The early diagno-
sis of this impairment is of crucial importance, since
dietary PUFA balance may contribute towards the pre-
vention and the control of such diseases [2]. Recent sci-
entific evidence has disclosed a correlation between the
bioavailability of n-3 PUFA and the prevention or treat-
ment of various neurological disorders, such as adult de-
pression, schizophrenia, dyslexia, dyspraxia, autism and
attention deficit/hyperactivity disorder in children
(ADHD) [3], [4], [5], [6] [7]. The authors of a retrospect-
ive study including 1188 elderly American subjects sug-
gested that low levels of circulating docosahexaenoic
acid (DHA) may be a significant risk factor for the de-
velopment of Alzheimer dementia. They related inability
to maintain a high level of DHA with a reduced capacity
to synthesize DHA late in life resulting from a reduction
in Δ6 desaturase activity [8]. Moreover it was postulated
that abnormalities in phospholipid fatty acid compos-
ition may play a role also in psychiatric disorders, in-
cluding depression, changing membrane fluidity and,
consequently, influencing various neurotransmitter sys-
tems, which are believed to be related to the pathophysi-
ology of major depression [9]. Depletion of n-3 fatty acid
levels in red blood cell membranes of depressed patients
has been previously reported [10] [11].
Our laboratory has developed and validated a rapid
method to analyze the fatty acid composition and the
arachidonic acid / eicosapentanoic acid (AA/EPA) ratio
in whole blood in the Italian population; the method
provides a parameter that correlates directly with
erythrocyte phospholipid fatty acid composition [12].
On the basis of these observations, the aim of the
present double-blind placebo-controlled study was to
compare the AA/EPA ratio in depressed and non
depressed elderly subjects and to evaluate the role of n-3
PUFA supplementation in the treatment of depression in
the elderly.
It is well known that n-3 PUFA modify cellular im-
mune responses both in vitro and in vivo [13] [14];
therefore, another aim of this study was to evaluate
CD2, CD3, CD4, CD8, CD16, CD19 lymphocyte subpo-
pulations, as well as some cytokines. In fact, numerous
studies have indicated major depression as an inflamma-
tory state with elevated levels of proinflammatory cyto-
kines, e.g. Interleukin IL-6, IL-12, interferon (IFN)-γ
[15], IL-1 and tumor necrosis factor (TNF)-α [16]. For
this reason we decided to evaluate cytokines that have
not yet been sufficiently studied to date, such as IL-5
and IL-15, in this study. A possible correlation between
these cytokines and depression has been postulated onthe basis of the increased genetic risk for major depres-
sion associated with the colony stimulating factor 2 re-
ceptor β (CSF2RB) haplotype, which encodes a protein
in high affinity receptors binding IL-5 [17]. Furthermore,
a gene set analysis of post-mortem brain tissue has
suggested that IL-5 levels may be up-regulated in
major depression [18]. Moreover, T regulatory cells
may play a role in depression through down regulation
of chronic inflammatory responses [19]. Based on the
notion that T cells may subserve neuroprotective and
anti-inflammatory functions during stress and inflam-
mation, impaired T cell function may directly contribute
to the development of depression [20]. Literature meta-
analyses in this area have also revealed that depression
and stress are associated through decreased lympho-
cytes and T cells in plasma [21].Material and methods
Subjects
Eligible participants were females with age ranging be-
tween 65 and 95 years, who were recruited in a nursing
home in Pavia, where they had been institutionalized
for at least 3 months prior to enrolment. The protocol
was approved by the Ethics Committee of the Azienda
Sanitaria Locale (ASL – Local Health Unit) of Pavia
and all subjects gave their written consent to the study.
Data were gathered from 31st January 2006 to 31st
January 2007.
Exclusion criteria included neurologic conditions other
than depression and other psychiatric disorders that
could have accounted for the observed psychotic distur-
bances. Moreover, subjects with clinically uncontrolled
organic diseases or with clinically relevant laboratory ab-
normalities were excluded from the study. Medications
for other disorders (such as hypertension, insomnia, etc.)
were kept as constant as possible during the therapeutic
intervention (2 months).Study design
The study was a single-centre, 8-week, double-blind,
placebo-controlled, randomized, parallel-group study.
Included subjects were randomly assigned to the treatment
or the control group. Treatment group received one table-
spoon of a n-3 PUFA oil orally once a day (2.5 g/day with
EPA:DHA 2:1), before lunch, while the control group
received one tablespoon of placebo made of a paraffin oil,
with the same lemon flavour as the intervention product.
The n-3 PUFA oil was manufactured by Also S.p.A.,
Div. Also-Enervit, Zelbio (CO), Italy. Bottles of identical
oil for each treatment group were assigned a subject
number according to a coded (AB) block randomization
table prepared by an independent statistician. Investiga-
tors were blinded to the randomization table, the code
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rolled, they were assigned a progressive subject number.
Biochemical data obtained from depressed patients en-
rolled in the study were compared with those of a third
group of healthy subjects not directly involved in the
study. To this purpose, data obtained from our labora-
tory data base were selected taking into account, health,
sex and age. Seventy-six healthy subjects, with the same
median age, were selected for the comparison. The sub-
jects were then divided into groups, taking into account
the use of omega-3 supplements: 42 healthy subjects
declared that they were taking 2.5 g/day of omega-3
PUFA regularly, while 34 declared that they were not
taking any kind of fatty acid supplement.
For experimental purposes, subjects were indicated
as: 1) Omega-3 Before (depressed subjects assigned to
the treatment group before the start of omega-3 sup-
plementation), 2) Omega-3 After (depressed subjects
after omega-3 supplementation), 3) Placebo Before
(depressed subjects assigned to control group before
taking placebo), 4) Placebo After (depressed subjects
after the use of placebo), 5) Healthy Before (healthy
subjects that were not taking supplements), 6) Healthy
After (healthy subjects that were taking omega-3 sup-
plements regularly).
Psychological evaluation
Patients were required to have a Mini-Mental State
Examination (MMSE) score higher than 24 [22]. All the
patients underwent a neurologic and psychiatric evalu-
ation for the diagnosis of depression. First of all, the
guidelines for diagnosis of major depressive disorder and
dysthymic disorder were used by a senior psychiatrist, as
reported in the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM IV) [23]. In
addition to this evaluation, the presence of depressive
symptoms was assessed through the use of the Geriatric
Depression Scale (GDS) [24]. The GDS Long Form is a
30-item questionnaire in which participants are asked to
respond by answering yes or no in reference to how they
felt over the past week. Scores of 0–9 are considered
normal, depending on age, education and complaints;
10–19 indicate mild depression and 20–30 indicate se-
vere depression. No intervention other than the admin-
istration of omega-3 fatty acids was performed for
depression. Subjects were asked not to change their
everyday activities.
Blood analyses
In all the recruited subjects, fasting fresh blood samples
were collected by venipuncture in EDTA separator tubes
and promptly applied to peripheral blood mononuclear
cells (PBMC) isolation by Ficoll Density Gradient, using
LSM 1077 Lymphocyte Separation Medium (PAA,Pasching, Austria) and centrifugation at 2200 rpm for 20
minutes at 20°C. The intermediate layer consisting of
PBMC was washed twice in HANKS's medium (PAA)
containing 0.1% BSA and 0.5 mM EDTA and twice with
DMEM Buffer (PAA) containing 2 mM EDTA and 0.5%
BSA. After blocking of nonspecific antibody binding, the
following monoclonal antibodies and appropriate isotype
controls were used for flow cytometry: CD2, CD3, CD4,
CD8, CD16, and CD19 (all BD); (MBL International,
Woburn, MA). Flow cytometric analysis was performed
on a FACS Canto-II (BD). The acquired data were ana-
lysed by FlowJo software (TreeStar, Ashland, OR). Num-
bers of circulating cells were assessed by the percentage
of the respective cell subset multiplied by the respective
subset of absolute cell count obtained from routine
blood count. Serum levels of IL-5 and IL-15 were mea-
sured by ELISA using commercial kits (BIOSOURCE
International, Camarillo, CA).Lipid analyses
Regarding the lipid profile, the analysis was carried out
blind to the subject status. Whole blood and purified
erythrocyte (RBC) cell membranes were used for lipid
assessment.
RBCs were separated from plasma by centrifugation
and stored at −70°C until used for analysis. Cell mem-
branes of RBC (ghosts) were prepared by lysis with
hypotonic buffer (phosphate 5 mM pH 8, EDTA 0. 5
mM) and washed several times to eliminate haemoglo-
bin residues. Ghost lipids were extracted with chloro-
form/methanol according to Folch [25] and fractionated
by silicic acid chromatography (200–400 mesh BIORAD)
into non polar lipids, glycolipids and phospholipids Red
blood cell membrane phospholipids were analyzed by
quantitative thin-layer chromatography to identify each
species [26].
Each phospholipid species (Phosphatidyl-ethanolamine,
PE; Phosphatidyl-inositols, PI; Phosphatidyl-serine, PS;
Phosphatidyl-choline, PC; Sphingomyelin, SM) was further
purified by HPLC-ELSD as previously described [27].
Fatty acid composition of whole blood, total RBC
membrane phospholipids and of each phospholipid spe-
cies purified form RBC membrane was determined by
gas-chromatographic analysis. Whole blood was directly
derivatized without any further purification.
The fatty acid methylesters were obtained after derivati-
zation with sodium methoxide in methanol 3.33% w/v and
injected into gas chromatograph (Agilent Technologies
6850 Series II) equipped with a flame ionization detector
(FID) under the following experimental conditions: capil-
lary column: AT Silar length 30 m, film thickness 0.25 μm.
Gas carrier: helium, temperature: injector 250°C, detector
275°C, oven 50°C for 2 min, rate of 10°C min-1 until 200°C
Figure 1 GDS (mean±SE) in depressed elderly patients before
and after supplementation with Placebo or omega-3 PUFA.







Before 14.339 31.296 37.010







































Rizzo et al. Nutrition Journal 2012, 11:82 Page 4 of 11
http://www.nutritionj.com/content/11/1/82for 20 min. A standard mixture containing methyl ester
fatty acids was injected for calibration.
Statistical analysis
The sample size was computed on the basis of the pri-
mary end-point of the study (i.e. Geriatric Depression
Scale, GDS). To detect a 20% difference in the GDS be-
tween the n-3 PUFA and the placebo groups, with an
SD of the GDS equal to 4, a minimum of 23 subjects per
group were needed, with alpha=0.05 and beta=0.2. Data
were analysed through the use of the statistical software
package SAS version 9.1 (Cary, NC, USA). To compare
depressed and non depressed subjects, as well as post-
treatment to baseline values, we used Student’s paired t-
test or Wilcoxon signed-rank test, according to the
result of the normality test. Similarly, to compare base-
line values and changes from baseline between treatment
and placebo groups, we used unpaired t-tests or
Wilcoxon rank sum test. Normality was assessed using
the Shapiro-Wilk test. Correlations between changes
from baseline in GDS and AA/EPA, with a number of
anthropometric, nutritional and biological covariates
were tested by calculating the Spearman rank-order cor-
relation coefficients. P-values <0.05 were considered to
be statistically significant.
Results
A total of forty-six female subjects were enrolled.
Twenty-two patients were randomly allocated to the
intervention group (Omega-3 group, 2.5 grams EPA:
DHA 2:1), and 24 to the placebo group. Population char-
acteristics were similar in both groups, as shown in
Table 1. The omega 3 supplement was well tolerated,
and there were no serious adverse events over the 8 wk
of the study.
At baseline, the intervention group showed a mean
GDS value of 17.1±3.7, while the placebo group had a
mean GDS of 16.7±4.3 At the end of the study, the mean
GDS score diminished significantly only in the Omega-3
group down to 11.6±4.3 (Figure 1). Figure 2 reports the
AA/EPA ratio in whole blood (panel A) and in erythro-
cyte membrane phospholipids (panel B) of depressed
subjects. For comparative purposes a group of healthy
elderly subjects with the same median age who were ta-
king (before) or not taking (after) omega-3 supplementsTable 1 Baseline characteristics of the depressed subjects
Omega-3 group Placebo group
N subjects studied 22 24









Before 33.785 79.970 77.878
After 6.565 68.937 42.291
0
Figure 2 AA/EPA ratio in whole blood (panel A) and in RBC
membrane phospholipids (panel B) in healthy subjects and
depressed elderly patients before and after supplementation
with Placebo or omega-3 PUFA. **P<0.01 After vs. Before; §§
P<0.01 Depressed vs. Healthy.
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line, the AA/EPA ratio was significantly higher in
depressed subjects than in healthy ones. At the end of
the study, the AA/EPA ratio decreased significantly in
the patients who had taken the omega-3 supplement
(intervention group), while it did not change in the placebo
group, both in whole blood or in the RBC phospholipids.
Anyhow, these values appeared to be significantly higher
than the AA/EPA ratio observed in both groups of healthy
subjects who were or were not taking omega-3 supple-
ments. The AA/DHA ratio in whole blood did not show
significant changes after treatment (7.13±1.92 vs 7.01±2.36
in the omega-3 group: data not shown).
Figure 3 reports the correlation between the changes
in AA/EPA ratio (Before-After) and the change in GDS
(Before-After) in depressed elderly patients treated with
Placebo (panel A) and n-3 PUFA (panel B). In the pla-
cebo group the data are scattered along the axes,
whereas in the n-3 PUFA group all the data are posi-
tioned in the positive quadrant. This finding indicates
that there is a correspondence between the amelioration
of the psychological condition (as assessed by a decrease
of GDS score) and the n-3 PUFA treatment (as assessed










































Figure 3 Correlations between the decrease in AA/EPA ratio (Before-A
patients treated with Placebo (panel A) and Omega-3 PUFA (panel B)Figure 4 compares the EPA and DHA content (% of
total fatty acids) in whole blood and RBC membranes of
the healthy and depressed subjects included in the study.
In the depressed elderly subjects The content of EPA
(panel A) in blood and RBC membranes was significantly
lower in the depressed elderly subjects than in the
healthy ones. The content of EPA was increased in blood
after n-3 PUFA supplementation in depressed subjects,
but it did not reach the level of healthy volunteers taking
omega-3. Conversely, after omega-3 supplementation the
level of EPA in RBC membranes in depressed subjects
reached the levels of healthy subjects that were not ta-
king omega-3 (about 0.5%).
The level of DHA (panel B) was lower in the blood of
depressed subjects than in the blood of healthy subjects;
conversely, the concentration in RBC membranes did not
differ when healthy and depressed subjects were compared.
The DHA content of blood was not increased after supple-
mentation, while a slightly significant increase was found
in RBC membranes (from 3.22 to 4.055%).
The phospholipid species present in erythrocyte
membranes of depressed subjects were purified and
analyzed in order to determine their fatty acid compos-
ition (Figure 5). EPA (panel A) was incorporated in the15 25 35 45
AA/EPA  (Before-After)




fter) and the change in GDS (Before-After) in depressed elderly
.
Figure 4 EPA (panel A) and DHA (panel B) % concentration in whole blood and in erythrocyte membrane (RBC) in healthy subjects
and depressed elderly patients before and after supplementation with placebo or omega-3 PUFA. *P<0.05; **P<0.01 After vs. Before; §§
P<0.01 Depressed vs. Healthy before.
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phospholipids. A slight increase in PI was also found,
but it was not statistically significant. Conversely, DHA(panel B) was incorporated exclusively in PC, although a
slight, albeit non significant increase was measured also
in PE and PS.
A








Before 0.690 0.556 0.279 0.319 0.208 0.155 0.357 0.257 0.244 0.243
After 0.711 0.988 0.372 0.502 0.203 0.252 0.365 0.398 0.249 0.229






















Before 6.748 5.911 2.205 2.676 8.245 6.776 1.658 1.203 0.859 0.971
After 6.806 7.090 2.724 2.470 8.178 7.581 1.909 1.657 0.811 1.042







Figure 5 EPA (panel A) and DHA (panel B) % concentration in specific phospholipids of erythrocyte membrane (RBC) in depressed
elderly patients before and after supplementation with placebo or omega-3 PUFA. *P<0.05; **P<0.01 After vs. Before; PE
phosphatidylethanolamine, PI phosphatidylinositol; PS phosphatidylserine; PC phosphatidylcholine; SM sphingomyelin.
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distribution (data not shown).
As far as immunological parameters are concerned,
CD16 changed in relation to n-3 PUFA supplementation,
with a significant increase in the blood of depressed sub-
jects (Table 2).
Table 3 reports the correlation between changes pre
and post treatment in the depressed subjects after n-3
PUFA supplementation, for all the studied parameters.
A significant positive correlation was found between
GDS and FT3, CD3, CD4 and CD4/CD8. The AA/EPA
ratio in blood correlated positively with CD19 and
CD16, while the AA/EPA ratio in membranes correlated
negatively with CD2.
Discussion
Depression is common in late life: both major and minor
depression are reported in 13% of community dwellingolder adults, 24% of older medical out-patients, 30% of
older acute care patients and 43% of nursing home
dwelling older adults [28]. Depression is often reversible
with prompt and appropriate treatment. However, if left
untreated, depression may result in the onset of physical,
cognitive and social impairment, as well as delayed re-
covery from medical illness and surgery, increased health
care utilization and suicide. A wealth of evidence indi-
cates that consumption of fish or dietary fish oils contain-
ing long-chain n-3 PUFA, is associated with cardiovascular
benefits, including a reduction in circulating triglycerides
and reduced mortality from coronary heart disease [29].
Moreover, n-3 PUFA have been proposed as potential
treatment of depressive disorders [30]. Lower concentra-
tions of n-3 PUFA are associated not only with cognitive
impairment and dementia, but also with depression, a po-
tential risk factor for cognitive decline [31]. Our data
clearly demonstrate that elderly depression is characterized
Table 2 Immunological parameters: pre and post treatment immune marker comparison between the two groups of
depressed subjects
Omega-3 group (n=22) Placebo group (n=24) Tests
Pre-treatment Post-treatment Pre-treatment Post-treatment
Mean (Std.dev.) Mean (Std.dev.) Mean (Std.dev.) Mean (Std.dev.) 1 2 3 4
CD2 84.2 (12.2) 82.9 (12.9) 88.4 (5.5) 87.9 (8.0)
CD19 9.0 (10.9) 10.6 (10.2) 6.2 (4.5) 10.9 (18.3)
CD3 66.1 (12.8) 66.5 (12.9) 69.8 (8.8) 70.6 (9.6)
CD4 41.4 (14.3) 39.1 (16.3) 44.4 (7.9) 41.4 (11.9)
CD8 31.9 (13.4) 29.1 (13.9) 29.5 (8.1) 30.9 (9.6)
CD16 13.0 (9.3) 16.5 (10.8) 12.4 (6.2) 15.0 (8.6) *
CD4/CD8 1.58 (0.96) 1.68 (1.17) 1.66 (0.85) 1.45 (0.64)
IL-5 1.69 (0.60) 1.89 (1.28) 4.36 (8.22) 3.23 (5.90)
IL-15 5.86 (3.88) 8.11 (6.14) 5.88 (3.32) 5.99 (5.41)
1 Student’s paired t-test or Wilcoxon signed-rank test to compare post-treatment to baseline values within n-3 group.
2 Student’s paired t-test or Wilcoxon signed-rank test to compare post-treatment to baseline values within placebo group.
3 Unpaired t-test or Wilcoxon rank sum test to compare baseline values between n-3 and placebo group.
4 Unpaired t-test or Wilcoxon rank sum test to compare changes from baseline values between n-3 and placebo group.
* p<0.05.
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RBC membranes compared to healthy subjects. In this
study, the supplementation with 2.5 grams/day of n-3
PUFA for eight weeks with an EPA/DHA ratio 2:1 reduced
the GDS of the depressed subjects. This positive result
appears to be related to the chosen supplementation proto-
col used in the study. As a matter of fact, the inconsistence
of the outcomes of different meta-analyses has been
ascribed to differences in dose and type of the n-3 PUFA
supplements used for the treatment of major depression
(MDD). Martins et al. [32] reviewed recently the effects of
n-3 PUFA dosages from 1 g to 6 g/day as well as of EPA
and DHA alone or in different combinations of TG or
ethyl esters for different treatment periods. These authors
concluded that n-3 PUFA supplementation is beneficial in
adult patients with MDD, but that its effect is strongly
dependent upon the EPA content of the regimen. Thus,
studies employing regimens containing more than 60% of
EPA showed a highly significant pooled standard mean dif-
ference estimate, whereas those containing less than 60%
of EPA did not .
Omega-3 supplements used at different EPA:DHA ratios,
such as 1.2:1 at higher doses, were able to increase both
EPA and DHA concentration in RBC membranes in adults
affected by moderate hypertriglyceridemia [33].
In this study, daily supplementation with 2.5 g/day of
n-3 PUFA with EPA/DHA content of 2:1 appeared able
to restore only EPA concentration in RBC membrane to
normal values, while the blood EPA and DHA concen-
trations after supplementation did not increase to the
value observed in healthy subjects. Moreover, in this
study, after supplementation in depressed subjects EPA
appeared to be enriched in PE, PS and PC of RBCphospholipids, while DHA selectively increased in PC.
This may be relevant for the production of PUFA meta-
bolites from phospholipids, arising from second messen-
gers and intracellular signals.
In fact n-3 PUFA, especially DHA, are increasingly
being recognized as reservoirs of lipid messengers for
neuronal cells, [34]; [35]. Specific precursors are cleaved
from membrane phospholipids, in particular from PC,
upon stimulation by neurotransmitters, neurotrophic
factors, cytokines, membrane depolarization, ion channel
activation. The lipid messengers, such as neuroprotec-
tins, that originate from the cleaved DHA regulate and
interact with multiple signalling cascades, contributing
to the growth, differentiation, function, protection and
repair of the nervous system [36]. From this point of
view, our data demonstrate that in depressed subjects
the level of DHA is preserved in RBC membranes while
it is decreased in whole blood. After n-3 PUFA supple-
mentation, the incorporation of DHA exclusively in PC
of membrane phospholipids may favor the production of
DHA metabolites.
The incorporation of PUFA in the phospholipid's
sn-2 acyl chain differs, depending on the brain area
considered. For instance, it has been demonstrated
that the cortex (where DHA levels are very high) is
particularly affected by n-3 PUFA deficiencies [37].
In particular, prolonged dietary deficiency leads to
decrements of DHA in the order of 40% in the
frontal cortex and striatum of mice. DHA brain defi-
ciency has important neurological consequences [38];
for instance, when maintained on an n-3 deficient
diet, rats or mice exhibit poorer performance in the
Y-maze [39] and spatial learning [37] tests. These
Table 3 Correlation (Spearman, non parametric) between
changes pre/post treatment in omega-3 treated
depressed subjects of the studied variables (GDS and AA/







HGB −0.16 −0.30 −0.36
HCT −0.08 −0.15 −0.21
WBC −0.13 −0.32 0.10
Lymphocytes −0.10 −0.15 −0.22
RBC 0.14 −0.23 −0.02
MCV −0.13 −0.06 −0.03
Plt 0.15 −0.14 −0.11
Ferritin −0.02 −0.17 −0.05
Serum Iron 0.25 −0.15 −0.28
Transferrin −0.21 −0.03 −0.05
Triglycerides −0.11 −0.14 −0.16
Total Cholesterol −0.05 −0.39 −0.04
HDL −0.08 −0.15 −0.24
Total Protein −0.21 −0.05 −0.04
Albumin −0.17 −0.07 −0.31
Creatinine 0.31 −0.02 −0.12
Sodium 0.38 −0.12 −0.06
Potassium −0.11 −0.26 −0.09
Chlorine −0.22 −0.10 −0.12
Calcium −0.04 −0.04 −0.23
Uricemia −0.17 −0.45 * −0.04
Glycemia −0.01 −0.15 −0.18
Folic Acid −0.32 −0.07 −0.40
Vitamin B12 −0.15 −0.40 −0.12
TSH −0.03 −0.21 −0.28
FT3 −0.56 ** −0.19 −0.36
FT4 −0.05 −0.27 −0.14
CD2 −0.18 −0.40 −0.45 *
CD19 −0.27 0.43 * −0.35
CD3 −0.48 * −0.12 −0.26
CD4 −0.47 * −0.26 −0.23
CD8 −0.21 0.18 −0.18
CD16 −0.39 0.50 * −0.22
CD4/CD8 −0.48 * −0.21 −0.12
IL-5 −0.04 −0.01 −0.30
IL-15 −0.20 0.45 −0.18
* p<0.05; ** p<0.01.
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equate amounts of omega-3 fatty acids [40]. More-
over, the action of mood stabilizers, such as lithium,carbamazepine, sodium valproate, or lamotrigine, in
bipolar disorders has been linked to arachidonic acid
turnover in brain phospholipids [41]. Lithium has
proved to reduce AA, but not DHA turnover select-
ively in phosphatidylinositol, phosphatidylcholine, and
phosphatidylethanolamine [42].
Our data might reflect what is really happening in the
brain of depressed subjects, indicating a n-3 PUFA defi-
ciency, which is partially corrected after supplementation.
When n-3 PUFA concentration is low, abnormal func-
tion and metabolism of various neurotransmitters has
been observed in addition to reduced activity of recep-
tors associated with G-proteins and ionic channels. For
instance, n-3 PUFA facilitate hippocampal synaptic
transmission by targeting presynaptic nicotinic Ach
receptors under the influence of protein kinase C (PKC)
[43]. Therefore, a reduction of DHA and EPA body stor-
age may limit the learning process and may imply de-
rangement of cerebral activity [44].
Various experimental studies demonstrate a positive
correlation between decrease in n-3 PUFA and abnormal
activity of dopaminergic, noradrenergic and serotoniner-
gic systems [45]. In vitro, serotonin reuptake, a site of
action for many antidepressants, is increased by n-3
PUFA [46]. In animal models, chronic dietary n-3 fatty
acid deficiency is associated with increased extracellular
serotonin (5-HT) concentrations, increased levels of 5-
hydroxyindoleacetic acid (5-HIAA) and increase in 5-
HIAA/5-HT ratio in the brain [47]. Moreover, preclinical
data provide evidence supporting a functional link be-
tween n-3 PUFA deficiency and increased central 5-HT
turnover, [48]; [49]. It has also been shown that n-3
PUFA modulates the expression of dopamine and sero-
tonin receptors [50]. These observations are relevant,
because it is well known that most depression events are
associated with impairment of the serotoninergic and –
at least in part- of the adrenergic system [51]. Recent
data on animal models demonstrate that supplementa-
tion with n-3 PUFA produces antidepressant effects
mediated by an increase in serotonergic neurotransmis-
sion, particularly in the hippocampus [52].
As regards immunological parameters, to our know-
ledge this is the first study that examines the relationship
between n-3 PUFA levels and immunological parameters
i.e. CD2, CD3, CD4, CD8, CD16, CD19 lymphocyte sub-
populations and IL-5 and IL-15, in depressed elderly sub-
jects, who received either n-3 PUFA supplements or
placebo.
It is known that n-3 PUFA deficiency impairs cellular
aspects of the immune response [53] and a combination
of clinical, animal and in vitro studies suggest that con-
sumption of n-3 PUFA has potential therapeutic effects
in the treatment of inflammatory and autoimmune dis-
eases [54], although the results are conflicting.
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http://www.nutritionj.com/content/11/1/82In the present study, no differences were found either
in the intervention or in the placebo group, when pre
and post treatment immunological indices were com-
pared, with the exception of the increase in CD16
lymphocyte subpopulation in the n-3 PUFA group. Data
from animal models and humans [55] have indicated
that monocyte subsets considerably change with age. Ac-
tually it appears that CD16 monocytes can be crucial
players in infection and inflammation, but the formal
demonstration of their role in these pathological condi-
tions will require selective elimination of these cells
in vivo [56].
A previous study indicated that the circulating mono-
cyte pool dynamically changes during ageing in humans.
The expansion of the non-classical CD14+CD16+ sub-
type, alterations of surface protein and chemokine recep-
tor expression, as well as circulating monocyte-related
chemokines, likely allow the preservation of monocyte
pool function throughout the majority of adulthood [57].
In this study, the correlation among immunological
parameters, GDS score and AA/EPA ratio in blood and
membrane, was surprisingly modest. We speculate that
age-related immune imbalance might be the cause of
these poor correlations, as already suggested by other
authors [62]. Therefore, further studies are needed in the
field of n-3 PUFA and immunity in elderly subjects.
Conclusion
In conclusion, this study confirms the positive effects of
n-3 PUFA supplementation in the treatment of elderly
depression. It also demonstrates that n-3 PUFA status
may be monitored by means of the determination of
whole blood AA/EPA ratio.
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